Biotech entrepreneur Michael Torres is selling his antibody-drug conjugate startup CrossBridge Bio to Eli Lilly in a deal worth up to $300 million, the two

The FDA has launched a drive to get clinical trial sponsors to disclose the results of studies – even if they are negative.

At a moment when many drug developers are shying away from politically charged mRNA vaccines, one prominent research funder is doubling down on the technology’s

Seeking an R&D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.